Review article · 2023 · Open access
B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
Frontiers in Immunology, 14, 1126421 · Published 10 February 2023 · DOI 10.3389/fimmu.2023.1126421
In brief
“B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?” is a 2023 review article by Zheng Zhang and 2 co-authors, published in Frontiers in Immunology. OpenAlex counts 82 citations as of 20 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 82
- Most cited in
- 2025 (29)
- Field-weighted impact
- 1.84
- References
- 86
- Authors
- 3
Abstract
Immune system detects foreign pathogens, distinguishes them from self-antigens and responds to defend human body. When this self-tolerance is disrupted, the overactive immune system attacks healthy tissues or organs and the autoimmune diseases develop. B cells and plasma cells contribute a lot to pathogenesis and persistence of autoimmune diseases in both autoantibody-dependent and autoantibody-independent ways. Accumulating data indicates that treatments aiming to eliminate antibody-secreting cells (B cells or plasma cells) are effective in a wide spectrum of autoimmune diseases. Monoclonal antibodies (mAbs) deplete B cell lineage or plasma cells by signaling disruption, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Engineered-T cells armed with chimeric antigen receptors (CARs) have been adopted from field of hematological malignancies as a method to eliminate B cells or plasma cells. In this review, we update our understanding of B cell depletion therapies in autoimmune diseases, review the mechanism, efficacy, safety and application of monoclonal antibodies and CAR-based immunotherapies, and discuss the strengths and weaknesses of these treatment options for patients.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhang, Z., Xu, Q., & Huang, L. (2023). B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy? Frontiers in Immunology, 14, 1126421. https://doi.org/10.3389/fimmu.2023.1126421
MLA 9
Zhang, Zheng, et al. “B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?” Frontiers in Immunology, vol. 14, 2023, p. 1126421. https://doi.org/10.3389/fimmu.2023.1126421.
Chicago
Zhang, Zheng, Qian Xu, and Liang Huang. 2023. “B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?” Frontiers in Immunology 14: 1126421. https://doi.org/10.3389/fimmu.2023.1126421.
Harvard
Zhang, Z., Xu, Q. and Huang, L. (2023) ‘B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?’, Frontiers in Immunology, 14, p. 1126421. doi:10.3389/fimmu.2023.1126421.
IEEE
Z. Zhang, Q. Xu, and L. Huang, “B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?,” Frontiers in Immunology, vol. 14, p. 1126421, 2023, doi: 10.3389/fimmu.2023.1126421.
BibTeX
@article{zhang2023cell,
title = {{B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?}},
author = {Zhang, Zheng and Xu, Qian and Huang, Liang},
journal = {Frontiers in Immunology},
year = {2023},
volume = {14},
pages = {1126421},
doi = {10.3389/fimmu.2023.1126421},
url = {https://doi.org/10.3389/fimmu.2023.1126421}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 8 | |
| 2024 | 22 | |
| 2025 | 29 | |
| 2026 | 23 |
Its field-weighted citation impact is 1.84: it has been cited 1.84 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- B-cell depletion therapy
- autoimmune disease
- monoclonal antibodies
- chimeric antigen receptor T cells
- CAR T-cell therapy
- plasma cells
- autoantibodies
- complement-dependent cytotoxicity
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Zhang, Z., Xu, Q., & Huang, L. (2023). B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy? Frontiers in Immunology, 14, 1126421. https://doi.org/10.3389/fimmu.2023.1126421
How many times has this paper been cited?
82 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Zheng Zhang, Qian Xu, Liang Huang.
What is the DOI of this paper?
10.3389/fimmu.2023.1126421, permanently at https://doi.org/10.3389/fimmu.2023.1126421. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.